Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Gunther Birznieks Sells 42,431 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Gunther Birznieks sold 42,431 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,904.37. Following the completion of the sale, the senior vice president directly owned 494,197 shares in the company, valued at $4,087,009.19. This trade represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Vanda Pharmaceuticals Trading Up 4.6%

Shares of NASDAQ VNDA traded up $0.36 during trading on Wednesday, reaching $8.20. The company had a trading volume of 1,262,325 shares, compared to its average volume of 4,505,636. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $9.60. The business’s 50-day moving average is $7.56 and its 200 day moving average is $5.97.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The firm had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. On average, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing for Vanda’s sNDA for HETLIOZ (tasimelteon) in jet lag disorder — described as a landmark action and the first drug approval hearing in over 40 years. This raises the chance for public review and could materially affect approval timing and outcome. PR Newswire
• Positive Sentiment: HC Wainwright maintains a Buy view with a $24 price target and issued updated quarterly EPS forecasts for FY2027 (Q1–Q4 estimates provided). The firm’s constructive outlook and high price target support upside sentiment despite near-term losses. MarketBeat VNDA
• Neutral Sentiment: Technical/volume and valuation context — the stock is trading above its 50-day and 200-day moving averages, market cap is roughly $485M and the company remains loss-making (negative P/E). Current intraday volume is below the 3-month average, which may mute short-term moves. MarketBeat VNDA
• Negative Sentiment: Significant insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and two SVPs (Gunther Birznieks and Timothy Williams) each sold large blocks on March 2 (each sale ~30k–156k shares, representing single-digit percentage reductions in their holdings). Multiple high-level executive sales can be perceived negatively by investors and may pressure sentiment even if sales are for diversification or tax reasons. Relevant SEC filings: CEO (Read More.), CFO (Read More.), CMO (Read More.), SVP Gunther Birznieks (Read More.), SVP Timothy Williams (Read More.).

Institutional Trading of Vanda Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Torren Management LLC purchased a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $25,000. Russell Investments Group Ltd. grew its stake in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the period. CWM LLC increased its holdings in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 7,575 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Vanda Pharmaceuticals by 3,010.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 10,055 shares during the period. Finally, Jain Global LLC bought a new stake in Vanda Pharmaceuticals during the 4th quarter worth approximately $94,000. Institutional investors own 88.14% of the company’s stock.

Wall Street Analyst Weigh In

VNDA has been the subject of a number of research analyst reports. B. Riley Financial lifted their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, December 31st. Jefferies Financial Group lifted their target price on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research report on Wednesday, December 31st. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Finally, UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $14.13.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.